A method and medicament for treating mixed lineage leukemia； translocatedmixedlineage leukemia； translocated mixed lineage leukemia based acute myelogenousleukemia； translocated mixed lineage leukemia based acute lymphoid leukemia； anon-MLL based chronic myeloproliferative disorder, or non-MLL based acutelymphoid leukemia is provided, wherein the active agent used is the GSK-3inhibitor7-(2,5-dihydro-4-imidazo[ 1,2-a]pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1jk][1,4]benzodiazepine ora pharmaceutically acceptable salt or solvate thereof.
